The current treatments for RCC include molecularly targeted therapeutics such as multi-targeted receptor tyrosine kinase (RTK) or mTOR inhibitors that are widely used for patients with metastatic or recurrent RCC. The gene discussed is MTOR; the disease is renal cell carcinoma.